ArticleFrontiers in immunology2026
Inflammatory activity stratification improves liver stiffness diagnosis of fibrosis in autoimmune hepatitis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the correction value of inflammatory activity stratification on the diagnostic performance of liver stiffness measurement (LSM) for hepatic fibrosis in patients with autoimmune hepatitis (AIH), and to provide evidence for accurate fibrosis assessment in AIH patients. Methods: Clinical data of AIH patients who underwent liver biopsy at our hospital from January 2017 to January 2026 were retrospectively analyzed. All patients underwent LSM by transient elastography within the same period. Patients were divided into the G1-G2 group (mild-to-moderate inflammation) and G3-G4 group (severe inflammation) according to the simplified Scheuer inflammatory grade. Liver pathological fibrosis staging (S0-S4) served as the gold standard. Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic performance of LSM. A correction model was constructed by multivariate logistic regression and internally validated using the Bootstrap method with 1000 resamplings. Results: A total of 86 AIH patients were finally enrolled, including 79 females (91.9%) with a mean age of (54.1 ± 9.1) years. There were 52 patients in the G1-G2 group and 34 in the G3-G4 group. In the overall cohort, the area under the ROC curve (AUC) of LSM for diagnosing S≥2 fibrosis was 0.73 (95% CI: 0.62-0.83), with an optimal cutoff of 8.2 kPa. After inflammation stratification, the AUC in the G1-G2 group (0.85, 95% CI: 0.76-0.94) was significantly higher than that in the G3-G4 group (0.69, 95% CI: 0.54-0.84) (Z = 2.13, P = 0.033). The optimal cutoffs were 7.8 kPa and 9.1 kPa, respectively. A correction formula was established for the G3-G4 group: corrected LSM = raw LSM - 0.4 × inflammatory grade. After correction, the AUC for S≥2 increased to 0.85 (95% CI: 0.76-0.93), sensitivity from 55.0% to 86.7%, and specificity from 88.5% to 69.2% (all P<0.05). Conclusion: The diagnostic performance of LSM for fibrosis in AIH patients is affected by inflammatory activity, and severe inflammation leads to pseudo-elevation of LSM. The inflammation-stratified correction model significantly improves diagnostic accuracy and optimizes fibrosis staging in AIH patients. Further validation is required prior to clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.